187 related articles for article (PubMed ID: 25621798)
21. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
22. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
23. The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.
Fein JA; Shimoni A; Labopin M; Shem-Tov N; Yerushalmi R; Magen H; Furie N; Kopel E; Danylesko I; Nagler A; Shouval R
Leukemia; 2018 Aug; 32(8):1787-1794. PubMed ID: 29950692
[TBL] [Abstract][Full Text] [Related]
24. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
[TBL] [Abstract][Full Text] [Related]
25. Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia.
Kurosawa S; Yakushijin K; Yamaguchi T; Atsuta Y; Nagamura-Inoue T; Akiyama H; Taniguchi S; Miyamura K; Takahashi S; Eto T; Ogawa H; Kurokawa M; Tanaka J; Kawa K; Kato K; Suzuki R; Morishima Y; Sakamaki H; Fukuda T
Bone Marrow Transplant; 2013 Sep; 48(9):1198-204. PubMed ID: 23562971
[TBL] [Abstract][Full Text] [Related]
26. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
29. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
30. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
31. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
32. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
[TBL] [Abstract][Full Text] [Related]
33. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia.
Russell NH; Kjeldsen L; Craddock C; Pagliuca A; Yin JA; Clark RE; Howman A; Hills RK; Burnett AK;
Leukemia; 2015 Jul; 29(7):1478-84. PubMed ID: 25376374
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of pre- and 1-year post-transplant serum ferritin among adult transplant recipients.
Tachibana T; Tanaka M; Numata A; Matsumoto K; Tomita N; Fujimaki K; Taguchi J; Sakai R; Fujita H; Fujisawa S; Maruta A; Ishigatsubo Y; Kanamori H
Leuk Lymphoma; 2014 Jun; 55(6):1350-6. PubMed ID: 24024470
[TBL] [Abstract][Full Text] [Related]
35. Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.
Lim AB; Storek J; Beligaswatte A; Collins M; Tacey M; Williamson T; Mason K; Li E; Chaudhry MA; Russell JA; Daly A; Szer J; Lewis I; Ritchie D
Bone Marrow Transplant; 2015 Apr; 50(4):566-72. PubMed ID: 25642763
[TBL] [Abstract][Full Text] [Related]
36. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk.
Nivison-Smith I; Dodds AJ; Butler J; Bradstock KF; Ma DD; Simpson JM; Szer J
Biol Blood Marrow Transplant; 2012 Feb; 18(2):302-8. PubMed ID: 21620988
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: a multicenter experience from Argentina.
Basquiera AL; Pizzi S; Correas AG; Longo PG; Goldman WC; Prates MV; Formisano S; Kusminisky G; Feldman L; Berretta AR; García JJ; Staciuk R
Pediatr Blood Cancer; 2015 Jan; 62(1):153-7. PubMed ID: 25264233
[TBL] [Abstract][Full Text] [Related]
39. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
40. Increased bacterial infections after transfusion of leukoreduced non-irradiated blood products in recipients of allogeneic stem cell transplants after reduced-intensity conditioning.
Jaime-Pérez JC; Villarreal-Villarreal CD; Salazar-Riojas R; Méndez-Ramírez N; Vázquez-Garza E; Gómez-Almaguer D
Biol Blood Marrow Transplant; 2015 Mar; 21(3):526-30. PubMed ID: 25498924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]